

NEXT SCIENCE[®]

Quarter ending 31 December 2022 Investor Presentation

30 January 2023

Approved by the Board

Next Science Limited ABN 47 622 382 549

Suite 1902, Level 19, 821 Pacific Highway, Chatswood NSW 2067

Disclaimer

This presentation has been prepared by Next Science Limited (**Company**) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the *Corporations Act 2001* (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission (**ASIC**). It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company. This presentation should not be considered an offer or an invitation to acquire or sell, or a solicitation to invest in or refrain from investing in, new shares in the Company or any other financial products.

This document has been prepared based on information available as at the date of this presentation. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant or which a prospective investor may require in evaluations for a possible investment in the Company. It should be read in conjunction with the Company's periodic and continuous disclosure announcements which are available at www.nextscience.com and www.asx.com.au. The recipient acknowledges that circumstances may change and that this presentation may become outdated as a result. This presentation and the information in it are subject to change without notice. The Company is not obliged to update this presentation.

The information contained in this presentation does not constitute investment, legal, tax, accounting or financial product advice nor any recommendation to acquire securities in the Company. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (**Forward Statements**). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the **Next Science Parties**) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in \$USD unless stated otherwise.

An investment in Company shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director or partner of, or in the employment of, the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Next Science Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Next Science Parties: exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

Q4 2022 Highlights

Continuing to deliver annual growth

- Total product sales growth 2022 + 40% increase on pcp to \$11.3M (unaudited)
- Total revenue growth 2022 (unaudited) +31% to \$11.7M

Expanding portfolio to accelerate revenue growth

- Launched DME Business for the US wound care market in October, providing 1st reimbursed product for the Next Science direct to market
- To drive the growth of the DME business the direct wound care sales force is expanding and will continue to expand to support the business growth.



In October, NXS launched a DME business, staffed by a dedicated team of experienced wound care professionals who will drive the growth.

First commercial sales in Q4, 150 physicians offices are already prescribing

This business model provides a substantial increase in revenue per patient

Switching focus to direct sales in the US to drive growth

- 40% increase in product sales (unaudited) year on year, all driven by direct sales
- Major shift in channel mix to improve revenue results



- 18 October 2022, Next Science launched its new DME business
 - Expands direct sales portfolio by 1 product class (3 collagen products)
 - Provides a reimbursed product for the NXS wound care business
 - Expands wound care total addressable market from \$150M to \$1.4B
 - Provides the direct economic opportunity to support a larger direct sales force
 - Commercial sales underway - 150 Physicians offices already prescribing NXS products (10,000 Podiatry offices in the US)

Current markets now being served directly in the US

Chronic Wound Care

- 8.2 million patients in the US¹
- Causes deaths in 27.7% of patients within a 2 year period from first presentation.²
- Cost to US healthcare system to treat >\$50B pa²
- Segmented market – Federal market is deficit funded, so products are purchased based on efficacy;
- The commercial hospital market and private podiatry offices require products that are robustly reimbursed by Medicare/Medicaid and private Insurers.

Next Science offerings remove the biofilm and the bacteria and provide an environment to promote healing

Post Operative Surgical Complications

- Preventing surgical site infection (SSI)¹:
 - Total market 110 million surgical procedures pa¹
 - 2 million SSIs occurring per year in the US¹
- SSI causes 90,000 deaths pa¹
- Cost to US healthcare system to treat \$25-40B pa¹,
 - increased 36% in the past decade¹
- Preventative technologies included in 'Episode of Care' costs paid by insurance companies or by CMS (Medicare/Medicaid)

With XPERIENCE™ and SurgX™, Next Science is offering a suite of products to protect the patient from infection

FOCUS IS ON DRIVING COMMERCIAL SALES DIRECT AND WITH PARTNERS

Direct to market products from NXS in the US



BLASTX Antimicrobial wound gel for the treatment of chronic wounds.



Collagen Dressings for use in the treatment of chronic wounds



XPERIENCE Advanced Surgical Irrigation for the prevention of SSI



SurgX Sterile Topical Antimicrobial Gel for the prevention of SSI

Distributor partnerships outside the US

Zimmer Biomet distribute Bactisure globally, including Europe, the UK, Australia, New Zealand, South Africa and Latin America

Oraderm (Part of the Douglas Pharma and Apotex JV) distribute BlastX in Australia and New Zealand

Novus Surgical distributes XPERIENCE in Australia

Next Med distributes XPERIENCE and SurgX in New Zealand

tbh Skincare licenses Xbio technology in the Acne treatment market




NEXT SCIENCE®

Secured Convertible Notes

- To provide for working capital, NXS has entered into a A\$10M Secured Convertible Note Deed with Walker Group Holdings Pty Limited (NXS major shareholder) with a conversion price of A\$0.72, conditional upon shareholder approval being sought at a general meeting to be held on **2 February 2023**.
- Under the terms of the Note Deed, Walker Group has expressly agreed that if it elects to convert the notes into shares, NXS may undertake a capital raising by offering other shareholders an opportunity to subscribe for shares at the same share price (A\$0.72 per share) as the conversion.
- For further details, refer to NXS' ASX announcement on 13 December 2022 and the Notice of Meeting released on 30 December 2022.

Cash waterfall - YTD



Summary: Step up in marketing and sales activity driven by direct sales in 2023

Executing strategy to accelerate market awareness and adoption of Next Science's Xbio platform driven by direct sales activity from NXS

Delivering growth

- ✓ YTD product sales growth + 40% compared to pcp (unaudited)

Expanding markets and indications

- ✓ DME launched with 150 active physician offices prescribing by January 2023
- ✓ Xbio technology and research results were presented to over 5000 surgeons in congress settings from October to December 2022. Peer review publication expected in Q1 2023.
- ✓ Further independent research publications on positive results with Bactisure, XPERIENCE and BlastX , supporting commercial growth strategy (slide 25)

2023 - Growth and expansion

- ✓ Growing contributions from all products across the direct portfolio with increased confidence for XPERIENCE™ and accelerated plans for DME expansion
- ✓ CEO recruitment ongoing

Recent publications

Bashyal & James: [https://www.arthroplastyjournal.org/article/S0883-5403\(22\)00062-6/fulltext](https://www.arthroplastyjournal.org/article/S0883-5403(22)00062-6/fulltext)

Christopher, Tran, Vernon, Spangehl: <https://pubmed.ncbi.nlm.nih.gov/34740788/>

Kia et al: September 2021 <https://pubmed.ncbi.nlm.nih.gov/33529773/>

Knapp, Chen, Scuder, Mont: October 2021 [Surgical Technology International](https://www.surgicaltechnologyinternational.com/article/S0883-5403(22)00062-6/fulltext) 39DOI:[10.52198/21.STI.39.OS1514](https://doi.org/10.52198/21.STI.39.OS1514)

Parvin et al: <https://pubmed.ncbi.nlm.nih.gov/35629656/>

Plate, Zuskov, Seyler: https://journals.lww.com/jaaos/Citation/2021/12010/Use_of_Adjunct_Antiseptic_Agents_in_Periprosthetic.3.aspx

O'Donnell, Jams, Seyler et al: <https://journals.healio.com/doi/full/10.3928/01477447-20211227-05>

O'Donnell, James, Seyler et al: <https://pubmed.ncbi.nlm.nih.gov/33934664/>

Sosnoski et al: <https://pubmed.ncbi.nlm.nih.gov/36643380/>

Vickey, Hu, Parvan, Deva: <https://pubmed.ncbi.nlm.nih.gov/35629656/>

Whiteley et al: <https://pubmed.ncbi.nlm.nih.gov/35840981/>

Wu et al: <https://pubmed.ncbi.nlm.nih.gov/35158106/>

Nvarro, Sherman, Hamood et. al: <https://pubmed.ncbi.nlm.nih.gov/36358169/>

Fresquez, Chung, Pereira, et. al: Article accepted for publication, The Spine Journal

Newman, Roserough, Tamashiro et. al: <https://pubmed.ncbi.nlm.nih.gov/36324127/>

Myntti, Stevenson, Porral, et. al: <https://pubmed.ncbi.nlm.nih.gov/36645660/>

References

1. K Sen: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389759/>
2. https://www.researchgate.net/publication/51199135_High_mortality_in_patients_with_chronic_wounds
3. <https://www.definitivehc.com/blog/how-many-orthopedic-surgeons-in-us#:~:text=According%20to%20Definitive%20Healthcare's%20PhysicianView,hand%20surgery%2C%20and%20joint%20replacement>